

BEST AVAILABLE COPY  
BEST AVAILABLE COPY

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

## COMPOSITIONS FOR THE TREATMENT OF SKIN DISORDERS

### FIELD OF THE INVENTION

The present invention is generally in the field of compositions for topical application onto the skin intended to improve the skin's condition. The present invention provides method and compositions useful for improving various skin conditions, in particular acne.

### BACKGROUND OF THE INVENTION

Acne is a chronic inflammatory disorder of the pilosebaceous follicles, particularly in the face and neck region, occurring most commonly in adolescence between the ages of about 14 to about 19. Acne involves increased sebum secretion, hyperkeratinization in the infundibulum of the follicular duct, increased microbial colonization and inflammation (Strauss, J.S., *J. Dermatol. Treat.*, 1:3-6 (1989)). Various methods for the treatment of acne and other sebaceous glands' inflammation have been proposed, ranging from special diets, prevention of contact of the skin by known acneogenic agents (e.g., low grade cosmetics), use of endocrine preparations containing progesterone or estrogen, and others, most of which have not proved to be effective. Additionally, it has also been proposed to use antiseptic, antibacterial and wide-spectrum antibiotic compounds in both topical and systemic application.

All hitherto used anti-acne agents were effective in suppressing the development of microbial population, keratinization and comedo formation in the sebaceous glands. However, only few of the anti-acne agents hitherto used were effective in the reduction of the sebum excretion rate (Gollnick, H., *J. Dermatol. Treat.* 1:S23-S28 (1990) and none of the agents was useful in affecting lipid biosynthesis in the pilosebaceous unit.

Isoprenoid groups such as cholesterol, squalene and cholesteryl-esters are synthesized via the mevalonate pathway (Goldstein, J.L., Brown, M.S., *Nature*, **34B**, 425 (1990)), wherein the end-product is cholesterol. One of the key enzymes which regulate the production of mevalonate, the precursor of the above isoprenoid groups, is the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. Inhibitors of this enzyme inhibit the synthesis of cholesterol and are thus used as antihypercholesterolemic medicaments for the treatment of arteriosclerosis, hyperlipemia and related diseases. An example of such an inhibitor is Lovastatin (Merck Index 5460, U.S. 4,231,938). Pharmaceutical compositions comprising this inhibitor of HMC-CoA reductase are given orally or parenterally to patients suffering from arteriosclerosis or hyperlipemia.

## 20 SUMMARY OF THE INVENTION

In accordance with the invention it has surprisingly been found that acne can be treated by the use of a topically applied inhibitor of cholesterol synthesis. In accordance with the invention use is thus made with an inhibitor of cholesterol synthesis to treat various skin disorders.

25 In accordance with the present invention there is thus provided a composition for topical skin application comprising a carrier and, as an active ingredient, an effective amount of an inhibitor of cholesterol synthesis.

The composition of the invention may be a pharmaceutical or cosmetic composition.

The pharmaceutical composition of the invention may be used for various indications including acne vulgaris, psoriasis, scalp dandruff and  
5 saborea.

The present invention further concerns the use of inhibitors of cholesterol synthesis, for example inhibitors of the HMG-CoA reductase, for the preparation of topical pharmaceutical compositions for the treatment, alleviation or prevention of skin disorders.

10 Also provided by the invention is a method for improvement of skin condition comprising topically applying onto the skin a composition comprising a carrier and, as an active ingredient, an effective amount of an inhibitor of cholesterol synthesis. A particular application of the method is the treatment, alleviation or prevention of acne.

15 The term "*effective amount*" should be understood as meaning an amount of an active ingredient needed to achieve a desired therapeutic or pharmaceutical effect. For example, in a pharmaceutical composition of the invention an effective amount of an inhibitor of cholesterol synthesis is an amount which is sufficient, in the administration regimen of the pharmaceutical composition in the framework of treatment, to achieve an improve-  
20 ment in the skin's condition.

Inhibitors of cholesterol synthesis useful in accordance with the present invention are various agents which inhibit the production of the end product, i.e. cholesterol, or any of the intermediates of the various steps of  
25 the mevalonate pathway in which cholesterol is produced from the precursors acetyl CoA and acetoacetyl CoA. The inhibitors can be agents which inhibit the enzymes involved in the various steps or agents which serve as sequesters of the intermediates, both of which reduce the amount of cholesterol produced in this process.

In accordance with a preferred embodiment of the invention, the inhibitor of cholesterol synthesis is an agent which inhibits the HMG-CoA reductase, such as Lovastatin.

The concentration of the Lovastatin is preferably about 0.2 - 10%  
5 and most preferably about 2%.

The inhibitor of cholesterol synthesis may be applied to the skin with various other agents such as, antimicrobial agents, e.g. antibiotics, for the treatment or prevention of a secondary infection, a skin peeling agent, retin-A separately or together with resorcinol, etc.

10 The carrier of the composition of the present invention may be any pharmaceutically or cosmetically acceptable carrier such as, for example, ethanol, gel, liposome formulation, ointment, salve, etc.

## EXAMPLES:

### 15 I. Preparation of the Composition

Lovastatin capsules (Mevacor™, Merck, U.S.A.) were ground and the active ingredient was separated from the excipient by extraction with ethanol 95% and filtration to yield a 2% solution of Lovastatin in ethanol.

### 20 II. Clinical Trials

The efficacy of the above preparation was tested in two separate clinical trials.

#### A. Trial I

25 Pharmaceutical compositions prepared as described above were topically applied twice daily for a period of 12 weeks, to the faces of two individuals suffering from acne vulgaris. The patients were required to discontinue all other topical and systemic anti-acne treatment 30 days prior

to the beginning of the trial and discontinued all facial and cosmetic treatment seven days prior to the onset of treatment.

The acne condition was assessed by recording all acne lesions including inflamed acne lesions (papules and pustules) and non-inflamed  
5 acne lesions, (white and black comedos) prior to the beginning of treatment and 4, 8 and 12 weeks following the onset of treatment.

In both patients, improvement in all mentioned lesions was noticed and at the end of the 12 week treatment period the number of lesions decreased to less than half. No side effects were noticed save for a  
10 mild dryness of the skin, which is likely a result of the ethanol.

#### B. Trial II

4 patients, 16-25 years of age, consisting of 2 males and 2 females, having mild to moderate acne were treated with the above  
15 preparation. All medications and cosmetics were stopped for 14 days, following which the patients were asked to apply the preparation twice daily for 8 weeks and to refrain from using all other forms of treatment and cosmetics during treatment. Prior to and after 4 and 8 weeks of treatment,  
the number of acne lesions (papules, pustules and white and black comedos)  
20 was recorded, and the results, shown in the following Table 1 demonstrated an improvement in all 4 patients evidenced by reduction of the number of all types of lesions:

Table 1

Number of acne lesions before and during treatment

5	<b>Patient</b>	<b>Lesions</b>	<b>Before Treatment</b>	<b>After 1 month</b>	<b>After 2 months</b>
	1	Pustules Papules White & blackheads	10 11 18	7 3 10	3 2 7
	2	Pustules Papules White & blackheads	17 17 18	15 15 15	2 10 6
	3	Pustules Papules White & blackheads	7 12 22	2 7 14	- 4 7
	4	Pustules Papules White & blackheads	20 16 15	18 9 10	5 5 5
10	Average	Pustules Papules White & blackheads	13 14 18	10 8 12	2 5 6

**CLAIMS:**

1. A composition for topical skin application comprising a carrier and, as an active ingredient, an effective amount of an inhibitor of cholesterol synthesis.  
5
2. A composition according to Claim 1, being a pharmaceutical composition.
3. The pharmaceutical composition according to Claim 2, wherein the inhibitor of cholesterol synthesis is an inhibitor of the 3-hydroxy-3-methylglutary coenzyme A (HMG-CoA) reductase.  
10
4. A pharmaceutical composition according to Claim 3, wherein the inhibitor is Lovastatin.
5. A pharmaceutical composition according to Claim 4, wherein the concentration of the Lovastatin is about 0.2 - 10%.
- 15 6. A pharmaceutical composition according to Claim 5, wherein the concentration of the Lovastatin is about 2%.
7. A pharmaceutical composition according to any one of the preceding claims, for the treatment of a skin disorder selected from the group consisting of acne vulgaris, psoriasis, scalp dandruff and saborea.
- 20 8. A pharmaceutical composition for the treatment of acne according to Claim 7, comprising anti-acne agents selected from the group of: antimicrobial agents, peeling agents or various retinoeides.
9. Use of an inhibitor of cholesterol synthesis for the preparation of a topical pharmaceutical composition for the treatment, alleviation or  
25 prevention of skin disorders.
10. Use according to Claim 9 wherein the inhibitor of cholesterol synthesis is an inhibitor of 3-hydroxy-3-methylglutary coenzyme A reductase (HMG-CoA reductase).
11. Use according to Claim 10 wherein the inhibitor is Lovastatin.



12. A method for the treatment, alleviation or prevention of skin disorders comprising topically applying to the skin a pharmaceutically effective amount of an inhibitor of cholesterol synthesis.
13. A method according to Claim 12 wherein the inhibitor of  
5 cholesterol synthesis is an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA reductase).
14. A method according to Claim 13 wherein the inhibitor is Lovastatin.

# INTERNATIONAL SEARCH REPORT

Inten. .onal application No.  
PCT/US95/11678

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :A61K 31/35

US CL :514/460

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/460

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US, A, 4,231,938 (MONAGAHAN ET AL.) 04 November 1980, see entire document.	1-11

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	* T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
* A* document defining the general state of the art which is not considered to be of particular relevance	* X	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
* E* earlier document published on or after the international filing date	* Y	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
* L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	* A*	document member of the same patent family
* O* document referring to an oral disclosure, use, exhibition or other means		
* P* document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

18 JANUARY 1996

Date of mailing of the international search report

26 JAN 1996

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer  
JOHN H. FAY jd

Telephone No. (703) 308-1235

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record.**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ **BLACK BORDERS**

☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☐ **FADED TEXT OR DRAWING**

☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

☐ **SKEWED/SLANTED IMAGES**

☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

☐ **GRAY SCALE DOCUMENTS**

☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**

☒ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**